300759SZSE

Summary of the 2025 Annual Report

Pharmaron Beijing Co., Ltd.·

✨ AI Summary

This announcement provides a summary of the 2025 annual report for Pharmaron Beijing Co., Ltd., highlighting key financial figures and strategic decisions. The company achieved a revenue of approximately CNY 14.1 billion, a 14.82% increase from the previous year, while net profit attributable to shareholders decreased by 7.22% to CNY 1.66 billion. The report emphasizes the company's commitment to integrated services and international expansion, projecting a revenue growth of 12% to 18% for 2026.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Important Notes

This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial status, and future development plans, investors should carefully read the full annual report published in designated media by the China Securities Regulatory Commission. All directors attended the board meeting to review this report. Ernst & Young Hua Ming LLP provided a standard unqualified audit opinion on the company's financial report for the year.

Profit Distribution Plan

The profit distribution plan reviewed by the board during the reporting period is applicable. The profit distribution plan approved by the board is as follows: based on the total share capital of 1,830,020,328 shares after deducting the company's directly repurchased and held H shares (7,263,300 shares), a cash dividend of CNY 2 (tax included) will be distributed for every 10 shares to all shareholders, with no bonus shares issued. If there are changes in the total share capital during the distribution period due to new shares listing, equity incentives, share repurchases, etc., the total amount of distribution will be adjusted based on the total share capital on the record date for the distribution, maintaining the distribution ratio.

Company Overview

  1. Company Profile

    • Stock Abbreviation: Pharmaron
    • Stock Code: 300759.SZ/3759.HK
    • Stock Exchange: Shenzhen Stock Exchange
    • Contact: Secretary of the Board, Li Chengzong
    • Address: No. 6 Taihe Road, Beijing Economic and Technological Development Zone, Beijing
    • Fax: 010-57330087
    • Phone: 010-57330087
    • Email: pharmaron@pharmaron.com

  2. Main Business or Product Overview The company is a leading integrated pharmaceutical R&D service platform with a global presence, dedicated to assisting clients in accelerating drug innovation. It has 28 R&D centers and production bases in China, the UK, the USA, and Singapore, providing comprehensive drug research, development, and production services from drug discovery to drug development. The company continuously enhances the synergy of its service platform through vertical and horizontal integration, investing in new service capabilities and improving management efficiency to meet market and client demands.

Major Accounting Data and Financial Indicators

  1. Key Accounting Data for the Last Three Years The company does not need to restate or adjust previous years' accounting data.
    Year-EndTotal AssetsNet Assets Attributable to ShareholdersOperating RevenueNet Profit Attributable to ShareholdersNet Profit After Deducting Non-Recurring Gains and Losses
    202527,093,782,579.0415,064,159,256.0814,095,078,734.951,663,898,879.441,538,328,956.14
    202423,927,398,321.2313,619,333,910.0012,275,774,875.031,793,350,814.501,107,913,860.99
    202326,476,712,835.6012,556,797,361.4211,537,996,314.781,601,096,033.081,513,870,443.51

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Sign in to read moreSee Pro pricing